Literature DB >> 12608655

Promoter methylations of p16INK4a and p14ARF genes in early and advanced gastric cancer. Correlations of the modes of their occurrence with histologic type.

Hiroyuki Tsujimoto1, Akeo Hagiwara, Hiroyuki Sugihara, Takanori Hattori, Hisakazu Yamagishi.   

Abstract

The INK4a/ARF locus encodes two cell cycle-regulatory proteins, p16INK4a and p14ARF. These share an exon using different reading frames, and act through Rb and p53 pathways. Recently, it has been found that silencing of p16INK4a and p14ARF expressions by aberrant methylation of the CpG islands in the promoter regions is an alternative mechanism that inactivates possible tumor suppressor functions in various tumors. To clarify the features of gastric cancers with promoter methylation of p16INK4a and p14ARF, we investigated the methylation status in gastric cancer cell lines and primary gastric cancers using methylation-specific PCR (MSP), and correlated the methylation status with microsatellite instability (MSI), DNA ploidy pattern, p53 immunohistochemistry, and various clinicopathologic factors, paying attention to the correlations with the histologic types. Of 10 cell lines studied, silencing of the expression of p16INK4a and p14ARF due to promoter methylation was detected by MSP and RT-PCR in six (60%) and two (20%) cell lines, respectively. p14ARF silencing was detected only in cell lines derived from gastric cancer of the diffuse type, while p16INK4a silencing was found in cell lines derived from both diffuse and intestinal types. In 59 primary gastric cancers, promoter methylation of p16INK4a and p14ARF was found in 10 (17%) and 14 (24%) of the tumors independently, there being an association with DNA diploidy, but not with p53 immunohistochemistry. p16INK4a methylation was found irrespective of tumor stages and histology. Whereas p14ARF methylation was found more frequently in intestinal type cancers in an early stage and in diffuse type cancers in an advanced stage, MSI tended to be related especially to p14ARF methylation in cancers of the intestinal type. Thus, the significance of p14ARF methylation differed between intestinal and diffuse types, while such a difference was not observed in p16INK4a methylation.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12608655     DOI: 10.1078/0344-0338-00337

Source DB:  PubMed          Journal:  Pathol Res Pract        ISSN: 0344-0338            Impact factor:   3.250


  7 in total

1.  Role of p16 gene promoter methylation in gastric carcinogenesis: a meta-analysis.

Authors:  He-Ling Wang; Ping-Yi Zhou; Peng Liu; Yu Zhang
Journal:  Mol Biol Rep       Date:  2014-03-08       Impact factor: 2.316

Review 2.  Therapeutic targets in the ARF tumor suppressor pathway.

Authors:  Anthony J Saporita; Leonard B Maggi; Anthony J Apicelli; Jason D Weber
Journal:  Curr Med Chem       Date:  2007       Impact factor: 4.530

Review 3.  Primary adenocarcinomas of lower esophagus, esophagogastric junction and gastric cardia: in special reference to China.

Authors:  Li-Dong Wang; Shu Zheng; Zuo-Yu Zheng; Alan G Casson
Journal:  World J Gastroenterol       Date:  2003-06       Impact factor: 5.742

4.  BCL6 overexpression is associated with decreased p19 ARF expression and confers an independent prognosticator in gallbladder carcinoma.

Authors:  Peir-In Liang; Chien-Feng Li; Li-Tzong Chen; Ding-Ping Sun; Tzu-Ju Chen; Chung-Hsi Hsing; Han-Ping Hsu; Ching-Yih Lin
Journal:  Tumour Biol       Date:  2013-10-11

Review 5.  Dual Role of the Alternative Reading Frame ARF Protein in Cancer.

Authors:  Rosa Fontana; Michela Ranieri; Girolama La Mantia; Maria Vivo
Journal:  Biomolecules       Date:  2019-03-04

Review 6.  Transcriptional regulation of INK4/ARF locus by cis and trans mechanisms.

Authors:  Umer Farooq; Dimple Notani
Journal:  Front Cell Dev Biol       Date:  2022-09-09

7.  Progressive silencing of p14ARF in oesophageal adenocarcinoma.

Authors:  Yinghui Huang; Christopher J Peters; Rebecca C Fitzgerald; Ruth A Gjerset
Journal:  J Cell Mol Med       Date:  2008-04-09       Impact factor: 5.310

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.